• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

作者信息

Baccarani M, Pileri S, Steegmann J-L, Muller M, Soverini S, Dreyling M

机构信息

Department of Hematology-Oncology L and A. Seràgnoli, University of Bologna, Italy.

出版信息

Ann Oncol. 2012 Oct;23 Suppl 7:vii72-7. doi: 10.1093/annonc/mds228.

DOI:10.1093/annonc/mds228
PMID:22997458
Abstract
摘要

相似文献

1
Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.慢性髓性白血病：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2012 Oct;23 Suppl 7:vii72-7. doi: 10.1093/annonc/mds228.
2
Chronic myeloid leukemia: reaching for the cure.慢性髓性白血病：寻求治愈方法。
Curr Cancer Drug Targets. 2013 Sep;13(7):709-10. doi: 10.2174/15680096113139990091.
3
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.慢性粒细胞白血病的分子诊断与监测：BCR-Abl及其他
J BUON. 2009 Oct-Dec;14(4):565-73.
4
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.酪氨酸激酶抑制剂治疗新诊断的慢性髓性白血病
Hematol Oncol Clin North Am. 2017 Aug;31(4):577-587. doi: 10.1016/j.hoc.2017.04.006.
5
Present results and future perspectives in optimizing chronic myeloid leukemia therapy.慢性髓性白血病治疗优化的当前成果与未来展望。
Haematologica. 2018 Jun;103(6):928-930. doi: 10.3324/haematol.2017.182022.
6
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia.BCR-ABL的治疗靶点：慢性髓性白血病反应的预后标志物及耐药机制
Crit Rev Oncog. 2012;17(1):17-30. doi: 10.1615/critrevoncog.v17.i1.30.
7
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.酪氨酸激酶抑制剂时代的慢性髓性白血病：分子靶向治疗的不断演变模式
Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1.
8
Dasatinib in chronic myelogenous leukemia.达沙替尼治疗慢性粒细胞白血病
N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4.
9
Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era?在酪氨酸激酶抑制剂时代，慢性髓性白血病有可能被治愈吗？
Curr Opin Hematol. 2016 Mar;23(2):115-20. doi: 10.1097/MOH.0000000000000224.
10
When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?慢性髓性白血病患者何时可以停用酪氨酸激酶抑制剂？
Clin Adv Hematol Oncol. 2019 Feb;17(2):101-103.

引用本文的文献

1
Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies.波纳替尼治疗慢性髓性白血病且心血管风险增加的患者：管理策略综述
Hematol Transfus Cell Ther. 2025 Jan-Mar;47(1):103675. doi: 10.1016/j.htct.2024.04.124. Epub 2024 Aug 17.
2
Leukocytosis and thrombocytosis after splenectomy: expected finding, infection, or something else: a case report.脾切除术后白细胞增多和血小板增多：是预期的发现、感染，还是其他情况：一例报告。
J Med Case Rep. 2024 Oct 17;18(1):499. doi: 10.1186/s13256-024-04744-4.
3
JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib.
JAK2 作为伊马替尼治疗慢性髓性白血病患者治疗反应预测因子。
Dis Markers. 2024 Apr 12;2024:2906566. doi: 10.1155/2024/2906566. eCollection 2024.
4
Cost-Effectiveness Analysis of Transplantation-Ineligible Elderly Patients With Acute Leukemia Harboring a Molecular Target: Ph-Positive Acute Leukemia and FLT3-Mutated Acute Myeloid Leukemia.具有分子靶点的移植不适合的老年急性白血病患者的成本效益分析：费城染色体阳性急性白血病和FLT3突变急性髓系白血病
J Clin Med Res. 2022 Oct;14(10):432-435. doi: 10.14740/jocmr4799. Epub 2022 Oct 28.
5
Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience.真实世界中伊马替尼治疗慢性髓性白血病患者的疗效和安全性结局：澳大利亚经验。
Pharmacol Res Perspect. 2022 Oct;10(5):e01005. doi: 10.1002/prp2.1005.
6
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.慢性期慢性髓性白血病治疗的临床医生视角。
J Hematol Oncol. 2022 Jul 11;15(1):90. doi: 10.1186/s13045-022-01309-0.
7
miR-497-5p induces apoptosis in K562 cells by downregulating ROCK1.miR-497-5p通过下调ROCK1诱导K562细胞凋亡。
Am J Transl Res. 2021 Aug 15;13(8):9278-9284. eCollection 2021.
8
CNS Involvement in a Patient with Chronic Myeloid Leukemia.慢性髓性白血病患者的中枢神经系统受累情况
Case Rep Hematol. 2021 Mar 11;2021:8891376. doi: 10.1155/2021/8891376. eCollection 2021.
9
Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review.慢性髓性白血病——从费城染色体到特异性靶向药物：文献综述
World J Clin Oncol. 2021 Feb 24;12(2):69-94. doi: 10.5306/wjco.v12.i2.69.
10
[The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)].《中国慢性髓性白血病诊断与治疗指南（2020年版）》
Zhonghua Xue Ye Xue Za Zhi. 2020 May 14;41(5):353-364. doi: 10.3760/cma.j.issn.0253-2727.2020.05.001.